

CF

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07H 1/00, 21/00</b>	<b>A1</b>	(11) International Publication Number: <b>WO 96/35699</b>  (43) International Publication Date: 14 November 1996 (14.11.96)
<p>(21) International Application Number: PCT/US96/06241</p> <p>(22) International Filing Date: 3 May 1996 (03.05.96)</p> <p>(30) Priority Data: 08/436,145 8 May 1995 (08.05.95) US</p> <p>(71) Applicant: NORTHWESTERN UNIVERSITY [US/US]; 633 Clark Street, Evanston, IL 60208 (US).</p> <p>(72) Inventors: LETSINGER, Robert, L.; 316 Third Street, Wilmette, IL 60091 (US). GRYAZNOV, Serge, M.; Apartment 212, 2 Clark Drive, San Mateo, CA 94401 (US).</p> <p>(74) Agent: KOHN, Kenneth, I.; Kohn &amp; Associates, Suite 410, 30500 Northwestern University, Farmington Hills, MI 48334 (US).</p>	<p>(81) Designated States: AU, CA, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: CHEMICAL LIGATION OF TEMPLATE-DIRECTED OLIGONUCLEOTIDES</p> <p>(57) Abstract</p> <p>A method of increasing oligonucleotide selectivity in recognition of nucleic acids is disclosed, the method including the steps of disposing in aqueous solution a first oligomer having high selectivity for a target polynucleotide and a second oligomer having high affinity for an adjacent segment of the target polynucleotide. The oligomers include first and second reactive groups capable of spontaneously and irreversibly forming stable covalent bonds between the oligomers in absence of added chemical reagents or enzymes. A method for hybridizing nucleic acids includes the steps of reversibly binding a first oligomer to a target oligo- or polynucleotide including base units complementary to base units of the oligonucleotide, reversibly binding a second oligomer to the target oligo- or polynucleotide including base units complementary to base units of the oligonucleotide adjacent to the first oligomer, and wherein one of the oligomers includes a nucleotide having a first reactive group proximate to a nucleotide of the other oligomer which includes a second reactive group capable of spontaneously forming a covalent bond with the first reactive group. The method further includes the steps of irreversibly covalently joining the oligomers together through the first and the second reactive groups having been brought in proximity to each other upon binding of the oligonucleotides on the target polynucleotide in the absence of added reagent or enzyme, dissociating the joined first and second oligomers from the target polynucleotide, and removing the target polynucleotide.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

## Chemical Ligation of Template-Directed Oligonucleotides

5           This application is a continuation-in-part  
of United States Serial No. 08/376,688, filed January  
23, 1995, which is a continuation of United States  
Serial Number 08/046,032, filed April 12, 1993, now  
abandoned.

10

**TECHNICAL FIELD**

          The present invention relates to a method of  
enhancing selectivity in recognition of nucleic acids  
15 and more specifically relates to methods having use as  
diagnostic methods for diseases or disorders involving  
mutations in nucleic acid sequences as well as  
therapeutic applications of oligonucleotides.

20

**BACKGROUND OF THE INVENTION**Oligonucleotides in Diagnostics.

          Oligonucleotide probes currently serve as  
useful tools in the diagnosis of genetic, bacterial,  
25 and viral diseases. In view of the rapid developments  
in molecular and cell biology, the research activity  
and the new leads in probe technology generated in  
industrial laboratories (Danheiser, 1994), and the  
rapidly expanding knowledge of the human genome, one  
30 can expect a growing list of new medical applications  
in the future.

          The basic idea underlying the probe  
technology is represented in Figure 1. The

-2-

polydeoxyribo- or polyribonucleotide target strands are immobilized on a solid surface, membrane, or bead. A probe oligonucleotide bearing a marker for identification is then added under stringent conditions  
5 for hybridization, so that the probe binds non-covalently and selectively to any region of the target in which the sequence is complementary to that in the probe. Residual probe oligonucleotide is then washed away from the immobilized target oligonucleotide, and  
10 the presence of any bound probe is observed by means of an attached reporter group. Common reporter groups include radioactive atoms (phosphorous, sulfur, carbon, or tritium), fluorescent or chemiluminescent groups, and enzymes that generate colored or fluorescent  
15 products. Some specific experimental procedures are given. (Jablonski et al, 1986; Urdea et al., 1988; Twomey and Krawetz, 1990; Lau et al, 1993; Maniatis et al., 1982). In practice, the techniques may be elaborated in a variety of ways, including use of  
20 chaotropes (van Ness and Chen, 1991), sandwich hybridization complexes (Urdea et al., 1989), and *in situ* hybridization (Roberts, 1990), and sensitivity can be increased by target amplification by the polymerase chain reaction (Gibbs, 1990) or by signal amplification  
25 (Urdea et al., 1989).

A limitation in the sensitivity of the probe technology arises from non-specific binding of the oligonucleotide probes to immobilized DNA or RNA targets. As noted by Roberts (1990): "Despite the many  
30 advances in the technique of *in situ* hybridization, the problem of nonspecific labeling, which creates false positive signals, plagues many researchers. In addition to binding to complementary nucleotide

-3-

sequences as they are supposed to, probes may also adhere to non-matching sequences, to proteins, and even to microscope slides." This problem is particularly acute when a single nucleotide mismatch in the probe  
5 and target sequence occurs.

One needs relatively long oligonucleotide sequences to achieve good affinity in binding to the target. Generally probes in the 20 to 40 nucleotide range are used. Also, for unique recognition of genes  
10 in human DNA, it is estimated on a statistical basis that a minimum of 17 nucleotide units must be present in the probe. On the other hand, although binding affinity increases with increasing size of the probe, selectivity with respect to mismatches decreases. A  
15 mismatch in a long oligomer is less destabilizing than a mismatch in a shorter oligomer.

Oligonucleotides as Therapeutic Agents.

Synthetic oligonucleotides are being extensively used as sequence specific antisense agents  
20 (Helene 1990, Uhlman 1990, Crooke 1993), as well as probes for hybridization based detection assays of nucleic acids (Lowe 1986; Urdea 1988). Antisense oligonucleotides have demonstrated potential as new types of therapeutic agents for treating such diseases  
25 and disorders as viral diseases, cancer, genetic disorders, as well as other diseases and disorders (Bischofberger and Wagner, 1992). A problem encountered with the approach of utilizing antisense oligonucleotides as therapeutic agents concerns the  
30 selectivity of the agents in vivo: the antisense oligonucleotides can form complexes with targets that are not fully complementary. Relatively long oligomers (e.g. ~20-mers) are needed to provide a unique sequence

-4-

and a high binding affinity in targeting human genetic segments; however, the longer oligomers are not highly selective as antisense agents (Woolf, 1992). Short oligomers (e.g. 7-12 mers), which bind with low  
5 affinity, are much more effective in discriminating between complementary strands and targets containing one or more mismatches. In view of the low concentrations of intracellular polynucleotide targets and the low concentrations of therapeutic  
10 oligonucleotides that can be introduced into cells, it is recognized that there is a need for oligonucleotides with high binding affinities. The binding affinity is related to the length of the oligomers, preferably 20-mers and longer are desirable. But, in the case of  
15 long oligomers, a mismatch in base pairing is less destabilizing than in the case of a short oligomer. Hence, the desired destabilizing effect is lessened by the use of longer oligomers, while the selectivity is increased.

20 Experts have noted that "high sequence specificity" and "high affinity" are contradictory demands for an antisense oligonucleotide (NAMA Inter. Conference, 1993, pp 59-64), and have further concluded that it is probably not possible to stimulate cleavage  
25 of a specific RNA (and thereby inactivate it) by use of an antisense oligonucleotide without at least partial destruction of many non-targeted RNA's (Woolf, 1992). Hence, experts in the field, based on conducted research, have concluded that the conflicting  
30 requirements of high specificity and high affinity are major hurdles to overcome.

-5-

Chemical Ligation.

Several chemical methods have been reported for irreversibly covalently linking oligonucleotide blocks in aqueous media (Naylor and Gilham, 1966; 5 Sokolova et al, 1988; Shabarova, 1988; Chu, 1988; Kool, 1991; Ashley and Kushlan, 1991; Luebke and Dervin, 1991; Luebke and Dervan, 1992; Prakash and Kool, 1992; Purmal et al, 1992; Gryaznov and Letsinger, 1993b; Goodwin and Lynn, 1992). All of these methods require 10 an additional chemical agent to yield a stable ligated product. Depending on the approach, the added reagent may be an "activating agent" such as a water soluble carbodiimide or cyanoimidazole or it may be an oxidizing agent such as  $K_3Fe(CN)_6$  (Gryaznov and 15 Letsinger, 1993b) or a reducing agent such as sodium cyanoborohydride (Goodwin and Lynn, 1992). In any case, the need for the third reagent precludes chemical ligation *in vivo* since such compounds are toxic, react with water, and could not be introduced into living 20 systems in sufficient amounts to bring about the desired coupling reaction.

The present invention provides a novel method designed to capitalize on the positive features of both the longer and the shorter oligomeric reagents 25 to enhance selectivity in recognition of polynucleotide sequences. It is based on spontaneous and irreversible *in situ* chemical ligation (linking) of relatively short oligomer fragments equipped with electrophilic bromoacetamido and nucleophilic phosphorothioate groups 30 at their termini. Selective recognition is achieved without need for an additional condensing or stabilizing reagent. It therefore opens the door for *in situ* chemical ligation in living systems. Hence,

-6-

the present invention could solve the problem of the conflict of achieving both high affinity and high selectivity in therapeutic applications as well as in diagnostic and chemical amplification systems.

5                   Goodwin and Lynn (1992) have developed another system designed to enhance selectivity. Their approach utilized condensation of an amine with an aldehyde and was based on achieving "equilibrium between the transiently coupled and uncoupled  
10 substrates." This chemistry made necessary addition of another chemical agent (sodium cyanoborohydride) to reduce the reversible intermediate. As a consequence, their approach would not be suitable for use in living cells.

15

#### SUMMARY OF THE INVENTION AND ADVANTAGES

In accordance with the present invention, there is provided a method of increasing oligonucleotide selectivity in recognition of nucleic  
20 acids, the method including the steps of disposing in aqueous solution a first oligomer wherein the first oligomer has high selectivity for a target polynucleotide and a second oligomer has high affinity for the target polynucleotide. The oligonucleotides  
25 including first and second reactive groups capable of spontaneously and irreversibly forming covalent bonds between the oligomers when the oligonucleotides are aligned on a target polynucleotide.

Additionally, in accordance with the present  
30 invention, there is provided a method for hybridizing nucleic acids which includes the steps of reversibly binding a first oligomer to a target oligo- or polynucleotide including base units complementary to

-7-

base units of the oligonucleotide, reversibly binding a second oligomer to the target oligo- or polynucleotide including base units complementary to base units of the oligonucleotide adjacent to the first oligomer, and  
5 wherein one of the oligomers includes a nucleotide having a first reactive group proximate to a nucleotide of the other oligomer which includes a second reactive group capable of spontaneously forming a covalent bond with the first reactive group.

10 The method further includes the steps of irreversibly covalently joining the oligomers together through the first and the second reactive groups having been brought in proximity to each other upon binding of the oligonucleotides on the target polynucleotide in  
15 the absence of added reagent or enzyme, dissociating the joined first and second oligomers from the target polynucleotide, and removing the target polynucleotide.

An important feature of the chemistry utilized in the present invention is that covalent  
20 linkage of the two probes depends on a polynucleotide template and no additional activating agents or enzymes are needed.

#### BRIEF DESCRIPTION OF THE DRAWINGS

25 Other advantages of the present invention will be readily appreciated as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings wherein:

30 Figure 1 is a schematic representation of typical prior art hybridization probe methodology for screening for a point mutation wherein R represents a reporter group (e.g. a radioactive atom or a group than

-8-

can give an observable signal; the np's represent nucleotide units in a given polynucleotide sequence of an immobilized polynucleotide, Xp represents a point mutation, i.e., a nucleotide unit differing from that in the corresponding position in the sequence for the wild type polynucleotide, the np's represent nucleotide units in a probe complementary to the segment containing np's in a target probe; Xp represents a nucleotide complementary to Xp, ----- represents oligonucleotide segments in the target;

Figure 2 is a schematic representation of the hybridization technology of the present invention utilizing methodology I using a short, labelled probe and a longer unlabelled probe that undergo autoligation on an immobilized, matching polynucleotide (Target A), Y and Z represent functional groups (on the probes) which covalently and irreversibly join when the probes are aligned on the target polynucleotide, other notation is the same as in Figure 1;

Figure 3 is a schematic representation of oligonucleotides of the present invention for irreversibly coupling two probes (SEQ ID No:2) in order to detect a point mutation utilizing a two-probe-bridging technique for screening immobilized DNA samples for a ras mutant containing a single point mutation (replacement of C by T at the position indicated by underlining;

Figure 4 is a schematic representation of the hybridization technology of the present invention for transient target hybridization analysis wherein the notations have the same significance as in Figures 1 and 2;

-9-

Figure 5 is a schematic representation of the construction of oligonucleotides according to the present invention; and

Figure 6 is an IE HPLC of products from System I (1 + 2 + template 4a, 4b, or 4c) in buffer I, five minute reaction time: A, with 4a at 0°C; B, with 4a at 30°C; C, with 4b at 0°C; D, with 4b at 30°C, E, with 4c at 30°C; the peaks and assignments for A and B are, respectively: ~15.3 and 14.5 minutes (bromoacetamido derivative 2 and its hydrolysis product formed during analysis), 16.5 minutes (phosphorothioate 1); 20.9 minutes (template 4a), 21.5 minutes (product 3), the assignments are the same for B-F except templates 4a and 4b elute at ~22.5 minutes, after the product peak; the recorder sensitivity was 0.5 for A,B and 0.1 for C-F.

#### DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention there is provided a method of increasing oligonucleotide selectivity in recognition of nucleic acids, generally by the steps of disposing a first highly selective oligomer and a second highly  
affinitive oligomer in aqueous solution and then covalently binding the oligomers together.

By highly selective, it is meant that the degree to which the oligomer binds to its fully complementary strand is much greater than the degree to which the oligomer will bind to a non-complementary strand. A highly selective oligomer binds with high preference to the exact complementary sequence on a

-10-

target strand as compared to a sequence which has one or more mismatched bases.

By high affinity, it is meant that the dissociation constant for a complex formed from a probe  
5 and a target polynucleotide is very small. In other words, nucleotides sequences of the oligomer and the target polynucleotide are very closely related. That is, the oligomer and the target share a high degree of complementary base pair homology. Therefore, the high  
10 degree of complementarity provides for bonding forces which draw the complementary strands together and tends to keep the strands combined.

The present invention is based on the ligation chemistry developed by Gryaznov and Letsinger  
15 and demonstration that ligation of two oligomers by this chemistry shows a degree of selectivity with respect to proper base pairing that is characteristic for the selectivity exhibited by a short probe involved in the coupling (Gryaznov et al. 1994). This method  
20 exploits the fact that the coupling reaction described herein is very slow in very dilute aqueous solutions but is fast in the presence of a template polynucleotide. The reaction is accelerated in the presence of a target polynucleotide that possesses the  
25 sequence section complementary to the probe oligomers.

The ligation chemistry employs two short oligomers (for example, 8 to 20-mers) which will spontaneously link together covalently after binding at adjacent positions on a target polynucleotide. With  
30 this system, one will approach the binding affinity and recognition properties of a longer oligomer probe such as between 16 to 40-mer, but retain the dependency and

-11-

base pairing characteristics of the shorter probes (8 to 20-mer).

Examples of such pairs or reactive groups are ester+hydrazide,  $RC(O)S^-$ +haloalkyl and  $RCH_2S^-$ + $\alpha$ -haloacyl group, such as a bromoacetyl amino group and a thiophosphoryl group, which form a thiophosphorylacetyl amino bridge efficiently, selectively, and irreversibly in dilute aqueous media.

As demonstrated below, the products are stable in water and hybridize well with complementary polynucleotides.

At low oligomer concentrations, such as less than  $1\mu M$ , and in absence of a complementary template, the reactions are very slow but can be carried out to high conversion within a few days by freezing the solution. The freezing techniques are described in detail below. Coupling is quite fast (greater than 90% conversion in 20 minutes) when carried out in solution in the presence of a complementary oligonucleotide that serves as a template, as shown below in the Example section.

The present invention combines the advantages of short probes with respect to selectivity with the advantages of long probes with respect to affinity by utilizing two oligonucleotide probes that spontaneously link covalently, irreversibly, rapidly, and efficiently when aligned on an polynucleotide target. The method of the present invention can be applied both in diagnostic applications and in "antisense" therapeutic applications.

-12-

Diagnostic Applications.

The chemistry of the present invention is especially suitable for detection of point mutations. Two methods for utilizing the chemistry of the present invention in diagnostic applications are described below. One method (Method I) is adapted to the techniques for conventional probe work in which the target polynucleotide is immobilized. The second method (Method II) is based on a novel approach, made possible by the chemistry of the present invention, which involves transient immobilization of the target oligonucleotide.

Method I: The concept is generally indicated in Figure 2. The problem is to recognize a small amount of polynucleotide A in the presence, or absence, of polynucleotide B. In the region to be screened, A and B differ only in one nucleotide, X, or a few nucleotides. Two probe oligonucleotides are used. One is a short oligonucleotide (e.g. 7-20 nucleotides) containing a marker group (R) for detection, a nucleoside (X') complementary to X in the target (preferably positioned near the center of the probe) and a coupling group (e.g., bromoacetyl amino or phosphorothioate) at a terminus. The other probe is a longer oligonucleotide (e.g. 10-40 nucleotides) with an appropriate coupling group (bromoacetyl amino when a phosphorothioate group is used on the other probe or a phosphorothioate group when a bromoacetyl group is used on the other probe) at the end adjacent to the other probe when aligned on the target. On hybridization and coupling on the target polynucleotide (A) an extended probe is generated which binds cooperatively on the target. Excess unligated probes are then washed away

-13-

under stringent conditions for hybridization of the ligated probe (all unligated, labeled probe must be removed; it is not necessary to remove all of the unlabeled probe), and the presence of the ligated probe  
5 is detected via the marker group (via radioactivity, fluorescence, chemiluminescence, enzyme generated signals, etc.).

The chemistry of this new approach is indicated more specifically in Figure 3, which depicts  
10 how the method could be used to screen for a point mutation where T replaces C in a wild type genome.

Formulas for the mutant and wild type are shown below. The nucleotide at the mutation site is underlined.

15

mutant: (SEQ ID No:3)

3'...TpCpGpTpCpTpApCpCpApCpApApCpCpCpTpT.....

wild type: (SEQ ID No:4)

20 3'...TpCpGpTpCpCpApCpCpApCpApApCpCpCpTpT....

The structures of the probes for the assay and of the hybridized, bridged oligonucleotide formed after ligation are shown in Figure 3. In this case, a  
25 modification of the dot-blot procedure of Verlaan-deVries et al. (1986) could be used for the analysis.

In a variation of this method, both of the probe oligonucleotides could be labelled or carry reporter groups, the reporter groups on each would  
30 differ so that the signals could be read independently. for example, one reporter group might be fluorescent, colored, or chemiluminescent compound and the other label could be a radioactive marker. Positive

-14-

identification of a target polynucleotide could then be obtained when signals from both reporter groups are obtained after washing the immobilized target under stringent conditions for hybridization of the ligated  
5 oligonucleotide probes. In this case, it could prove advantageous to use oligonucleotide probes of about equal sizes. The method could also be extended to a three or more probe system in which two or more independent reporter groups are employed.

10               Method II: The "autoligation" chemistry opens the way for a new method of analysis that can be useful in screening samples for multiple point mutations. Some diseases, such as cystic fibrosis, can be caused by any one of several mutations in a gene. A  
15 convenient way to rapidly screen a sample for all the relevant mutations can, therefore, facilitate the genetic analysis. The reverse dot blot procedure of Y. Zhang et al., (1991), provides a means for such rapid screening. In this procedure, the probe oligonucleotide  
20 is bound to a surface and the target polynucleotide bearing a reporter or marker group is captured from solution as a hybridization product.

Method II is based on the reverse dot blot procedure. It differs in that both the target  
25 polynucleotide, which in this case has no reporter group, and a probe oligonucleotide, which does bear a reporter group, are captured transiently by an immobilized probe oligonucleotide. The new method is hereinafter termed "transient target hybridization  
30 analysis" since the method depends on the formation of a hybrid from the target polynucleotide and two (or more) probes, one of which is immobilized on a solid

-15-

support, as previously described, and another carries a marker group that can elicit a signal for detection.

Following hybridization and autoligation of the two probes, the hybrid complex is dissociated and  
5 the target oligonucleotide is removed from the region of the support and the immobilized ligated probes before the detection measurement. Removal of the target polynucleotide from the system prior to  
10 detection of the marker group (i.e. measurement of radioactivity, fluorescence, chemiluminescence, or ultraviolet or visible spectrum) is novel. The removal of the target polynucleotide minimizes background signals arising from adventitious, non-selective  
15 binding of the high molecular weight target polynucleotide to the solid support, as described above, in conventional diagnostic procedures. The concept for this method is illustrated in Figure 4.

In this approach, the longer, unlabelled probe is immobilized at a terminal position on a solid  
20 bead, membrane, or surface. The oligonucleotide can be covalently anchored at the 5'-position to the support via an amide bond formed from an amino linker on the oligonucleotide and a carboxy group on the membrane by the method of Y. Zhang et al., (1991), or through the  
25 3' position by an analogous coupling utilizing an oligonucleotide with a 3'-amino group, prepared as described by Gryaznov and Letsinger, (1992). Hybridization can then be carried out with a solution containing both the "short, labelled probe" and the  
30 target oligonucleotide.

Alternatively, the target polynucleotide can be hybridized first, under stringent conditions for that binding; the unbound target polynucleotide can

-16-

then be washed away; and hybridization can be carried out at a lower temperature under stringent conditions for binding the "short, labelled probe" to the target. Following autoligation of the two probes aligned on the  
5 target polynucleotide, the membrane (or other form of support) is washed again to remove excess labelled probe. The signal from the reporter group can then be read (e.g. radioactivity on the membrane determined, or chemiluminescence measured, etc.) Preferably, however,  
10 the hybridization complex is dissociated at this stage, e.g., thermally or by addition of alkali, and the liberated target polynucleotide and any "short, labelled probe oligonucleotide" that had been bound to it at any other site are washed away before the  
15 reporter signal is read.

In this example, the screening is designed for a single mutation. To screen simultaneously for many point mutations, an array of immobilized "long, unlabelled" probes could be used. The preparation of  
20 such arrays of probes on a membrane and analysis can, in principle, follow the procedures used by Y. Zhang et al., (1991), in the reverse dot blot method, with the modification indicated in discussion of Method II. The array consists of discrete spots on the membrane, each  
25 spot containing a unique probe covalently attached to the membrane. Hybridization is then carried out as in screening for a single point mutation (see Figure 4) except a mixture of "short, labelled oligonucleotide probes" is used rather than a single labelled probe.  
30 Each probe has a unique sequence complementary to one of the potential point mutations in the target polynucleotide. Also, the sequence of each labelled probe corresponds to an extension of the sequence of


-17-

one of the immobilize probes, so that, when the relevant mutation in the target is present, the oligomers will align on the target polynucleotide and undergo autoligation. The autoligation immobilizes the signal generating group at the spot of the immobilized probe. The analysis, therefore, generates a signal at each spot containing immobilized probes with sequences complementary to the sequence at a mutation site.

These methods, according to the present invention, have been illustrated for the case of two probe oligonucleotides. The methods can be extended to readily include autoligation involving three or more oligonucleotide probes. For example, for three probes, the following oligomers could be used. Also, the marker group R has been illustrated for:



or



the case where it is located at the 5' terminal position of a probe oligonucleotide. It could also be attached at any other position in the oligonucleotide that does not seriously compromise hybridization with the target, for example, at a nucleoside base ring, at a sugar position, or at the phosphate group. The R group could also be a substituent or an oligonucleotide segment that binds selectively to a fragment carrying a reporter group.

These methods for analysis of genetic material for mutations (Methods I and II) are made

-18-

possible by several findings of the applicants (Gryaznov and Letsinger, 1993a; Gryaznov et al., 1994). (1) Two oligonucleotides, in which one is terminated by a phosphorothioate group and the other by a bromoacetyl amino group, spontaneously couple rapidly and efficiently, with formation of an internucleoside phosphorylthioacetyl amino link (-OP(O)(O)(O)SCH<sub>2</sub>C(O)NH-), when bound contiguously on a matching oligonucleotide template. (2) The bridged oligomer that is formed binds with high affinity (approaching that of a corresponding oligonucleotide containing only phosphodiester links). The two oligonucleotide segments separated by the non-nucleotide bridge in the ligated product therefore act cooperatively in the hybridization reaction. (3) At the low oligomer concentrations employed in the template driven ligation (10<sup>-6</sup> M and less), ligation in the absence of a template oligonucleotide segment is extremely slow. (4) At appropriate temperatures (above the T<sub>m</sub> for a mismatched probe and below the T<sub>m</sub> for a matched probe) the rate of ligation on the template is highly dependent on the sequence of the template; a single mismatch leads to a great reduction in the rate of coupling.

25

#### Medical Applications.

oligonucleotides which have been modified to enhance stability and uptake in cells serve as effective inhibitors of synthesis of selected proteins in cells as is well known to those skilled in the art. As such they are useful tools for studies in biology. These oligonucleotides have also been found to be effective therapeutic agents in prolonging life in mice

-19-

with tumors. Clinical studies on the therapeutic effects of "antisense" oligonucleotides on humans are now in progress. The modified oligonucleotides therefore have potential as therapeutic agents in  
5 treating diseases. Much work has been done with methyl phosphonate and internucleoside phosphorothioate analogues. Several other modifications, including phosphoramidate derivatives, and oligomers with modifications at the base rings and sugar moieties may  
10 also be used.

The same features of the present invention that make the chemistry attractive for diagnostic applications also make it attractive for medical applications. These are the speed and efficiency of  
15 the coupling reaction, the high dependence of the reaction on presence of a complementary template polynucleotide, the stability of the covalent link that is formed in the ligation reaction, the absence of a requirement of presence of added reagents (e.g.  
20 condensing agents, reducing agents, or oxidizing agents), the cooperativity of the two ligated oligonucleotide fragments in binding to a complementary polynucleotide, and the enhancement in selectivity in recognition of oligonucleotide sequences association  
25 with use of two or more short oligonucleotide probes as compared with a single long probe.

The procedures for using the oligonucleotides of the present invention in antisense work can be the same as employed in conventional  
30 applications of antisense oligonucleotide. The only difference is that in the present invention two or more oligomers are employed in place of one, and that the oligomers contain reactive terminal functional groups

-20-

(e.g. 3'phosphorothioate at the terminal position of one oligomer and 5'bromacetyl amino at the terminal position of the other oligomer, or vice versa) that undergo spontaneous coupling when the oligomers align of the target polynucleotide in the cell, thereby affording an extended oligomer comparable to the single oligomer employed in a conventional system. In contrast to the diagnostics case, it is desirable here that each oligomer be about the same length. For example, in place of a twenty-mer conventional antisense oligonucleotide, one would use two ten-mers, each containing a terminal group to permit autoligation. Similarly, one could use three eight-mers, with appropriate terminal groups for coupling, in place of one twenty-four-mer. The oligomers used in this work can have the same modifications in the backbone, sugar, and base ring used in the conventional therapeutic and biological studies.

20

**EXAMPLES****Example 1**

For example, the present invention could be utilized in a diagnostic system as follows. The method of the present invention can be used as a diagnostic tool for detecting diseases or conditions which are caused by mutations in nucleic acid sequences such as sickle cell anemia, hepatitis C, viral infection, and cystic fibrosis.

30

The effect of mismatches on the efficiency of coupling was demonstrated in Method I. Method I is shown in Fig. 5.

-21-

**General Methods:**

Ion exchange high performance liquid chromatography (IE HPLC) was carried out on a Dionex Omni Pak NA 100 4x250 mm column at pH 12 (10mM NaOH) with a 2%/min. gradient of 1.5 M NaCl in 10 mM NaOH; 1 mL/min flow rate. For analyses in System I, the gradient solution also contained MeCN (2% by volume). Reversed phase (RP) HPLC was carried out with a Hewlett Packard Hypersil ODS 5  $\mu$ , 4.6x200 mm column at pH 7 in aq. 30 mM Et<sub>3</sub>N/HOAc with a 1%/min gradient of MeCN. Polyacrylamide gel electrophoresis (PAGE) was carried out with denaturing cross-linked 20% polyacrylamide gels (5% bis-acrylamide); R<sub>m</sub> values are relative to xylene cyanol. Except where otherwise noted, melting curves were obtained using solutions 0.10 M in NaCl, 5  $\mu$ M in each oligonucleotide, pH 7.0, by following changes in absorbance at 260nm while ramping the temperature at a rate of 1°C/min. Oligonucleotides were prepared via automated synthesis using standard cyanoethyl phosphoramidite chemistry. They were isolated with the DMT group intact and, following detritylation (80% aq. HOAc, 15 minutes), were purified by successive RP HPLC and IE HPLC.

**25 Preparation of CCTCTATT-P(0)(OH)S<sup>-</sup>**

This oligomer 3'-phosphorothioate was prepared by the procedure described by Gryaznov et al. (1994) starting with "3'-Phosphate CPG" supplied by Glen Research [DMTO(CH<sub>2</sub>)<sub>2</sub>SO<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>O-succinyl-lcaa CPG]. It was also prepared by the method reported by Gryaznov and Letsinger (1993a). In the former case, the DMT group was removed by DCA treatment and the support was phosphitilated with a DMT-thymidine

-22-

cyanoethylphosphoramidite reagent. Following sulfurization with a 5% solution of  $S_8$  in  $CS_2$ /pyridine (1/1 v/v) (45 minutes reaction) the oligomer (SEQ ID No:5) was synthesized by standard protocol. After  
5 isolation by preparative HPLC, the product eluted as a clean peak on RP HPLC (16.7 minutes) and on IE HPLC, pH 12 (16.4 minutes). It formed a complex with template 4a exhibiting  $T_m$  23°C (0.2 M NaCl); interaction with mismatched template, 4b, under the same conditions was  
10 very weak ( $T_m < 2^\circ C$ ). In support of the presence of a terminal thiophosphoryl group, oxidation of 1  $A_{260}$  unit of the oligomer in 10  $\mu L$  of water with 1  $\mu L$  of 1M aq.  $K_3Fe(CN)_6$  (three hours at 4°C) afforded a product eluting later on IE HPLC, as expected for oxidation of  
15 a terminal oligomer phosphorothioate to a dimeric disulfide derivative (Gryaznov and Letsinger, 1993a).

#### Preparation of $BrCH_2C(=O)NH-TGTCATCC$

To 5  $A_{260}$  units of  $NH_2-TGTCATCC$  (SEQ ID No:6)  
20 prepared as in Gryaznov and Letsinger (1993c); elution time 16.5 minutes for IE HPLC at pH 12;  $T_m = 32^\circ C$  with template 4a,  $T_m = 15^\circ C$  with mismatched template 4b in 15  $\mu L$  of 0.2 M sodium borate buffer, pH 8.5, at room temperature was added 15  $\mu L$  of 0.4 M N-succinimidyl  
25 bromoacetate in MeCN. After 30 minutes, the mixture was diluted to 0.5 mL with water and desalted on a NAP-5 column. The bromoacetamido derivative (3.5  $A_{260}$  units) was isolated by RP HPLC followed by lyophilization. It was homogeneous (~99% as a single peak) as judged by RP  
30 HPLC and by IE HPLC at pH 7 (30 mM  $Et_3N/HOAc$ , 10% MeCN with a 2%/min gradient of 1.0 M NaCl, 30 mM  $Et_3N/HOAc$ , 10% MeCN). When analyzed by IE HPLC at pH 12, however,

-23-

two peaks appeared -- a major peak (~75%) at 15.4 minutes and a minor one (~25%) at 14.5 minutes. Rechromatography of the product collected from the major peak again yielded the two peaks in about the same ratio. It was concluded that the minor peak is a degradation product (probably the hydroxyacetamido derivative) formed on exposing the bromoacetamido derivative to the strongly alkaline solution (pH 12) used in the chromatography. In agreement with this conclusion, the percentage of material in the faster eluting material increased to ~60% and then to >90% when the bromoacetyl derivative was exposed to a solution at pH 12 for 1 hour and for 2.7 hours, respectively, before chromatography.

15

#### Ligation Experiments

Ligations were carried out with 1  $\mu$ M solutions of each oligomer in an aqueous solution (buffer I: 15 mM sodium phosphate and 0.2 M NaCl, pH 7.0; or buffer II: 20 mM MES and 20 mM  $\text{MgCl}_2$ , pH 7.05; or buffer III: 0.1 M NaCl). At the end of the designated time an aliquot was injected in the HPLC unit for IE chromatography at pH 12. This pH was selected to denature oligonucleotide complexes in the system. The structure assigned to ligation product 3 is supported by the elution time on IE HPLC (close to values for 16-mers 4a-c) and the melting curve for the complex of 3 with 4a;  $T_m = 56^\circ\text{C}$  for 4  $\mu$ M of the complex in 0.1 M NaCl. Under the same conditions  $T_m = 62^\circ\text{C}$  for a natural phosphodiester duplex with the same nucleotide sequence.

25

30

Ligation studies with CCTCTATT-OP(0)(OH) $\text{S}^-$  (1) and  $\text{BrCH}_2\text{C}(0)\text{NH-TGTCATCC}$  (2) were carried out in

-24-

solutions 1  $\mu$ M in each oligomer at pH 7.0 (15 mM sodium phosphate and 0.2 M NaCl). Products were analyzed by ion exchange HPLC at pH 12. In absence of a template, no ligation was observed for reactions carried out for 5 45 minutes at either 0°C or 30°C. In marked contrast, rapid ligation occurred when an appropriate template was present. HPLC profiles are shown in Figure 6 for reactions carried out for five minutes at 0°C or 30°C in presence of a template (~10% excess template) that 10 was either fully complementary or contained one mismatch. The tallest peak in each profile corresponds to the template. The ligation product is the peak eluting immediately after the template (compound SEQ ID No:7) in Figure 6 (A, B) and just before the template 15 (compound SEQ ID No:8 or SEQ ID No:9) in Figure 4 (C,E). Residual thioate (1) appears at 16.5 minutes and the residual bromoacetamido derivative appears as a double peak at 14.5 and 15.3 minutes (the 14.5 peak is formed during chromatography at pH 12). At 30°C, the 20 ligation efficiency is markedly dependent on proper base pairing. From the peak areas, it is estimated that the conversion of 1 and 2 to 3 was approximately 75% when the fully matched template (4a) was present, Figure 6 (B), but ligation amounted to less than 5% 25 when a single mismatch occurred in a segment of the template binding to either oligomer 1, Figure 6 (D), or to oligomer 2, Figure 6 (F). Proper base pairing proved to be much less important at 0°C, where the binding affinity is much greater even when the template 30 has a mismatched base. At this temperature, conversion to the ligated product amounted to 85%, 78%, and 74% for mixtures containing 4a (Figure 6A, matched template) and 4b, and 4c (Figure 6 (C,E), mismatched

-25-

templates), respectively. When the reaction was carried out with a slight excess of the bromoacetamido derivative, 2, the yield of ligated product based on consumption of the limiting reagent, 1, was 94% and 97%  
5 for 4 minutes ligation on matching template 4a at 0°C and at 22°C, respectively.

Throughout this application various publications are referenced by citation or number. Full citations for the publications referenced by  
10 number are listed below. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

15 The invention has been described in an illustrative manner, and it is to be understood the terminology used is intended to be in the nature of description rather than of limitation.

Many modifications and variations of the  
20 present invention are possible in light of the above teachings. Therefore, it is to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described.

## REFERENCES CITED

- Ashley and Kushlan (1991) Biochemistry 30:2927-2933.
- Bischofberger and Wagner (1992) Virology 3:57-66
- Chu and Orgel (1988) Nucleic Acids Res. 16:3671-3691.
- Crooke & Lebleu, Ed. (1993) Antisense Research and Application (CRC Press, Boca Raton, Florida)
- Danheiser (1994) Genetic Eng. News, pp. 6-7
- Gibbs (1990) Analytical Chem. 62:1202-1214
- Goodwin and Lynn (1992) J. Am. Chem. Soc. 114:9197-9198.
- Gryaznov et al. (1994) Nucleic Acids Res. 22:2366-2369
- Gryaznov and Letsinger (1993a) J. Am. Chem. Soc., 115:3808-3809.
- Gryaznov and Letsinger (1993b) Nucleic Acids Res. 114:9197-9198.
- Gryaznov and Letsinger (1993c) Tetrahedron Lett. 34:1261-1264.
- Gryaznov and Letsinger (1992).
- Helene & Toulme (1990) Biochem. Biophys. Acta, pp. 99-125.
- Jablonski et al. (1986) Nucleic Acids Research 14:6115-6128
- Kool (1991) J. Am. Chem. Soc. 113:6265-6266.
- Lau et al. (1993) Lancet 341:1501-1504
- Letsinger & Wu (1994) Amer. Chem. Soc. 116:811-812
- Lewis (1986) Adv. Photochem 13:165-235
- Lowe (1986) Clinica Chimica Acta, 157:1-32.

-27-

Luebke and Dervan (1991) J. Am. Chem. Soc.  
113:7447-7448.

Luebke and Dervan (1992) Nucleic Acids Res.  
20:3005-3009.

Maniatis, et al. (1982) Molecular Cloning, Cold Springs  
Harbor Lab., pp.382-389

NAMA Proceedings, International Conference on Nucleic  
Acid Medical Applications, Cancun, Mexico, Jan 26-30,  
1993, pp. 59-63

Naylor and Gilham (1966) Biochemistry  
5:2722-2728.

Peters et al., J. Phys. Chem. 1993, 97:5482-5485.  
Prakash and Kool, J. Am. Chem. Soc., 1992, 114:3523-  
3527.

Purmal et al., Nucleic Acids Res., 1992,  
20:3713-3719.

Roberts (1990) J. NIH Res. 2:82-85

Salunkhe et al., J. Am Chem. Soc. 1992,  
114:8768-8772.

Shabarova, Biochimie, 1988, 70:1323-1334.

Sokolova et al., FEBS Letters, 1988, 232:153-155.  
Twomey and Krawetz (1990) Biotechniques 8(5):478-482

Uhlman & Peyman (1990) Chem. Rev. 90:544-548.

Urdea et al. (1988) Nucleic Acids Res.  
16:4937-4956.

Urdea et al. (1989) Clinical Chemistry, 35:1571-1575

van Ness and Chen (1991) Nuc. Acids Res.  
19:5143-5151

Vries et al., (1986) "A dot-blot screening procedurea  
for mutated ras oncogenes using synthetic  
oligodeoxynucleotides" Gene 50:313-320.

Woolf et al. (1992) Proc. Natl. Acad. Sci.  
88:7305-7309.

Zhang et al., (1991) "Single-base mutational analysis  
of cancer and genetic diseases using membrane bound  
modified oligonucleotides" Nucleic Acids Research, Vol.  
19, No. 14, pp. 3929-3933.

-29-

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Letsinger, Robert L.  
Gryaznov, Sergei M.
- (ii) TITLE OF INVENTION: METHOD OF FORMING OLIGONUCLEOTIDES
- (iii) NUMBER OF SEQUENCES: 9
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Reising, Ethington, Barnard & Perry
  - (B) STREET: P.O. Box 4390
  - (C) CITY: Troy
  - (D) STATE: Michigan
  - (E) COUNTRY: USA
  - (F) ZIP: 48099
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER:
  - (B) FILING DATE:
  - (C) CLASSIFICATION:
- (vii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: Kohn, Kenneth I.
  - (B) REGISTRATION NUMBER: 30,955
  - (C) REFERENCE/DOCKET NUMBER: P-323 (NW)
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (810) 689-3500
  - (B) TELEFAX: (810) 689-4071

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AGCAGATG

8

## (2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 10 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GTGTTGGGAA

10

## (2) INFORMATION FOR SEQ ID NO:3:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:3:

TTCCCAACAC CATCTGCT

18

## (2) INFORMATION FOR SEQ ID NO:4:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TTCCCAACAC CACCTGCT

18

## (2) INFORMATION FOR SEQ ID NO:5:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCTCTATT

8

## (2) INFORMATION FOR SEQ ID NO:6:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 8 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TGTTCATCC

8

-31-

## (2) INFORMATION FOR SEQ ID NO:7:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GGATGACAAA TAGAGG

16

## (2) INFORMATION FOR SEQ ID NO:8:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:8:

GGATGACAAA TAGTGG

16

## (2) INFORMATION FOR SEQ ID NO:9:

- (1) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 16 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

## (x1) SEQUENCE DESCRIPTION: SEQ ID NO:9:

GGTTGACAAA TAGAGG

16

-32-

## CLAIMS

1. A method of increasing oligonucleotide selectivity in recognition of nucleic acids by:

5 (a) reversibly binding a first oligomer to a target oligo- or polynucleotide including base units complementary to base units of the oligonucleotide, wherein the first oligomer has a relatively low affinity and high selectivity to the target  
10 polynucleotide;

(b) reversibly binding a second oligomer to the target oligo- or polynucleotide including base units complementary to base units of the oligonucleotide adjacent to the first oligomer, wherein  
15 the second oligomer has high affinity for the target polynucleotide, and wherein one of the oligomers includes a nucleotide having a first reactive group proximate to a nucleotide of the other oligomer which includes a second reactive group capable of  
20 spontaneously forming a covalent bond with the first reactive group; and

(c) irreversibly covalently joining the oligomers together through the first and the second reactive groups having been brought in proximity to  
25 each other upon binding of the oligonucleotides on the target polynucleotide in the absence of added reagent or enzyme.

2. A method as set forth in claim 1,  
30 wherein the first oligomer consists essentially of 7 to 20 nucleotides complementary to the target sequence.

-33-

3. A method as set forth in claim 1, wherein the second oligomer consists essentially of 10 to 40 nucleotides complementary to the target sequence.

5 4. A method as set forth in claim 1, wherein the first reactive group is a 3' or 5' terminal  $\alpha$ -haloacylamino group and the second reactive group is a 3' or 5' phosphothioate group, said step (c) being further defined as spontaneously forming a  
10 thiophosphorylacetyl amino bond through the reactive groups.

5. A method as set forth in claim 1 further including the step capturing the target oligo- or  
15 polynucleotide on a solid support.

6. A method as set forth in claim 5, wherein the solid support is further defined as a solid surface that binds the target nucleotide.

20

7. A method as set forth in claim 5, wherein the solid support is further defined as beads.

8. A method as set forth in claim 5,  
25 wherein the solid support is further defined as a membrane.

9. A method as set forth in claim 1 further including the step of labelling the joined oligomer in  
30 order to detect hybridization to the target oligo- or polynucleotide.

-34-

10. A method as set forth in claim 9, wherein the labelling step is further defined by attaching a labelled oligomer to either of the first or second oligomers..

5

11. A method as set forth in claim 9, wherein the labelling step is further defined by attaching a label to either of the first or second oligomers before hybridization to the target  
10 polynucleotide.

12. A method as set forth in claim 11 wherein the label on the first oligomer is  
15 distinguishable from the label on the second oligomer.

13. A method as set forth in claim 1 wherein steps (a), (b), and (c) occur in aqueous solution.

20

14. A method for hybridizing nucleic acids by:

(a) reversibly binding a first oligomer to a target oligo- or polynucleotide including base units  
25 complementary to base units of the oligonucleotide;

(b) reversibly binding a second oligomer to the target oligo- or polynucleotide including base units complementary to base units of the oligonucleotide adjacent to the first oligomer wherein  
30 one of the oligomers includes a nucleotide having a first reactive group proximate to a nucleotide of the other oligomer which includes a second reactive group

-35-

capable of spontaneously forming a covalent bond with the first reactive group;

(c) irreversibly covalently joining the oligomers together through the first and the second  
5 reactive groups having been brought in proximity to each other upon binding of the oligonucleotides on the target polynucleotide in the absence of added reagent or enzyme;

(d) dissociating the joined first and  
10 second oligomers from the target polynucleotide; and

(e) removing the target polynucleotide.

15. A method as set forth in claim 14, wherein the first oligomer has a relatively low  
15 affinity and high selectivity to the target polynucleotide.

16. A method as set forth in claim 14, wherein the second oligomer has high affinity for the  
20 target polynucleotide.

17. A method as set forth in claim 14, wherein three or more oligomers are bound contiguously and reversibly on the target polynucleotide.  
25

18. A method as set forth in claim 14, wherein the second oligomer is immobilized on an insoluble support.

30 19. A method as set forth in claim 14 further including the step of labelling the first oligomer in order to detect or measure the presence of the target polynucleotide.

-36-

20. A method as set forth in claim 14, wherein the first oligomer consists essentially of 7 to 20 nucleotides complementary to the target sequence.

5

21. A method as set forth in claim 14, wherein the second oligomer consists essentially of 10 to 40 nucleotides complementary to the target sequence.

10

22. A method as set forth in claim 14, wherein the first reactive group is a 3' or 5' terminal  $\alpha$ -haloacylamino group and the second reactive group is a 3' or 5' phosphothioate group, said step (c) being further defined as spontaneously forming a


15 thiophosphorylacetylamino bond through the reactive groups.


23. A method as set forth in claim 14 wherein steps (a), (b), (c), (d), and (e) occur in

20 aqueous solution.


24. A method for detecting point mutations as set forth in claim 14.








**Fig-4**



**Fig-5**

Fig-6

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06241

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 1/00, 21/00

US CL : 536/25.33; 24.5; 435/6; 935/77.78

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/25.33; 24.5; 435/6; 935/77.78.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

None

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS and CAS: chemical ligation; bromoacetyl; phosphorothioate; oligonucleotide#

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GOODWIN et al. Template-Directed Synthesis: Use of a Reversible Reaction. J. Am. Chem. Soc. 1992, Vol. 114, pages 9197 - 9198, especially page 9197.	1 - 24
A	THUONG et al. Synthèse et réactivité D'oligothymidylates substitués par un agent intercalant et un groupe thiophosphate. Tetrahedron Letters. 1987, Volume 28, Number 36, pages 4157 - 4160, especially page 4157.	1 - 24
A	CHU et al. Ligation of oligonucleotides to nucleic acids or proteins via disulfide bonds. Nucleic Acids Research. 1988, Volume 16, Number 9, pages 3671 - 3691, especially page 3672.	1 - 24

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance		
*E* earlier document published on or after the international filing date	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means		
*I* document published prior to the international filing date but later than the priority date claimed	*&*	document member of the same patent family

Date of the actual completion of the international search

07 JULY 1996

Date of mailing of the international search report

29 JUL 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Gary L. Kunz

Telephone No. (703) 308-1235

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/06241

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	GRYAZNOV et al. Chemical Ligation of Oligonucleotides in the Presence and Absence of a Template. J. Am. Chem. Soc. 1993, Volume 115, Number 9, pages 3808 - 3809, especially page 3808.	1 - 24
A	GRYAZNOV et al. Enhancement of selectivity in recognition of nucleic acids via chemical autoligation. Nucl. Acids Res. 1994, Volume 22, Number 12, pages 2366 - 2369, especially page 2366.	1 - 24